Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.
Sex Differences in the Use of Statins in Community Practice
Wang, Tracy Y., Xiang, Qun, Goldberg, Anne C. , Robinson, Jennifer G. , Roger, Véronique L. , Louie, Michael J. , Koren, Andrew , Li, Zhuokai , Nanna, Michael G. , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 16, 2019 | Volume: 12 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.118.005562 | PMID 31416347 Get It

Background: Female patients have historically received less aggressive lipid management than male patients. Contemporary care patterns and the potential causes for these differences are unknown. Methods and Results: Examining the Patient and Provider Assessment of Lipid Management Registry—a nationwide registry of outpatients with or at risk for atherosclerotic cardiovascular disease—we compared the use of statin therapy, guideline-recommended statin dosing, and reasons for undertreatment. We specifically analyzed sex differences in statin treatment and guideline-recommended statin dosing using multivariable logistic regression. Among 5693 participants (43% women) eligible for 2013 American College of Cardiology/American Heart Association Cholesterol Guideline–recommended statin treatment, women were less likely than men to be prescribed any statin therapy (67.0% versus 78.4%; P <0.001) or to receive a statin at the guideline-recommended intensity (36.7% versus 45.2%; P <0.001). Women were more likely to report having previously never been offered statin therapy (18.6% versus 13.5%; P <0.001), declined statin therapy (3.6% versus 2.0%; P <0.001), or discontinued their statin (10.9% versus 6.1%; P <0.001). Women were also less likely than men to believe statins were safe (47.9% versus 55.2%; P <0.001) or effective (68.0% versus 73.2%; P <0.001) and more likely to report discontinuing their statin because of a side effect (7.9% versus 3.6%; P <0.001). Sex differences in both overall and guideline-recommended intensity statin use persisted after adjustment for demographics, socioeconomic factors, clinical characteristics, patient beliefs, and provider characteristics (adjusted odds ratio, 0.70; 95% CI, 0.61–0.81; P <0.001; and odds ratio, 0.82; 95% CI, 0.73–0.92; P <0.01, respectively). Sex differences were consistent across primary and secondary prevention indications for statin treatment. Conclusions: Women eligible for statin therapy were less likely than men to be treated with any statin or guideline-recommended statin intensity. A combination of women being offered statin therapy less frequently, while declining and discontinuing treatment more frequently, accounted for these sex differences in statin use.
Developing a Newborn Resuscitation Telemedicine Program: A Follow-Up Study Comparing Two Technologies
McCauley, Kortany, Kreofsky, Beth L. , Suhr, Todd, Fang, Jennifer L.

Mayo Clinic

Telemedicine and e-Health | August 14, 2019 | Volume: 26 | Issue: 5 | Pages: 589-596

10.1089/tmj.2018.0319 | PMID 31411545 Get It

Altering the Traditional Approach to Restorative Proctocolectomy After Subtotal Colectomy in Pediatric Patients
Traynor, Michael D. , Moir, Christopher R. , Klinkner, Denise B. , Potter, D. Dean , Yonkus, Jennifer, Yonkus, Jennifer A.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | August 13, 2019 | Volume: 29 | Issue: 10 | Pages: 1207-1211

10.1089/lap.2019.0106 | PMID 31408401 Get It

Abstract Purpose: Restoration of intestinal continuity by ileal pouch-anal anastomosis (IPAA) following subtotal colectomy may not require a temporary, protective ileostomy. Diversion contributes to patient discomfort, cost, and additional operative risk at the time of subsequent reversal. We compared the outcomes of pediatric patients undergoing modified two-stage to three-stage IPAA after recovering from subtotal colectomy. Methods: We reviewed children (age <18) who underwent IPAA creation for ulcerative or indeterminate colitis from January 1, 2007 to December 31, 2017. Patient characteristics, operative details, 30-day complications, and postoperative length of stay (LOS) were abstracted. Total LOS for the three-stage group included both the IPAA and the ileostomy reversal operations. Univariate comparisons between patients undergoing modified two-stage and three-stage operations were performed. Results: A total of 43 patients underwent IPAA after subtotal colectomy; 32 (74%) underwent a three-stage approach, and 11 (26%) had a modified two-stage approach. Operative approach was laparoscopic in 33 (77%), planned open in 9 (21%), and converted to open in 1 (2%). Single-incision technique was used in 12 of 33 (36%) laparoscopic cases. Modified two-stage procedures had shorter total median LOS (7 days versus 9 days, P = .005). Incidence of postoperative leak, readmission, return to the operating room, and maximum 30-day Clavien–Dindo scores at the time of IPAA creation did not differ between modified two- and three-stage approaches (all P > .05). Conclusion: The modified two-stage approach to IPAA creation resulted in fewer hospital days compared to the three-stage approach. Considering the risks and patient burdens of diversion, further research is needed to assist in decisions regarding protective ileostomy after completion proctectomy with IPAA.
MLTI-07. PREOPERATIVE VERSUS POSTOPERATIVE STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES: AN INTERNATIONAL META-ANALYSIS
Garcia, Henry Ruiz, Peterson, Jennifer , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Harrell, Anna , Lehrer, Eric J. , Bhargav, Adip G. , Routman, David M. , Burns, Terry C. , Zaorsky, Nicholas G. , Trifiletti, Daniel M.

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i15-i16

10.1093/noajnl/vdz014.066 Get It

Abstract PURPOSE: Preoperative stereotactic radiosurgery (SRS) for symptomatic brain metastases has arisen as a therapeutic option for patients with brain lesions, potentially reducing radionecrosis risk, leptomeningeal disease risk, as well as delays in systemic therapy after craniotomy. The purpose of our work is to analyze the current evidence regarding 1-year local control (LC) and RN rates in the preoperative and postoperative settings. METHODS AND MATERIALS: Population, Intervention, Control, Outcomes, Study Design/Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology guidelines were used to select articles in which patients had “large” brain metastases (&gt;4 cm3 or &gt;2 cm in diameter) solely treated with preoperative or postoperative SRS and 1-year LC and/or rates of RN reported. Radiosurgery was stratified by timing: preoperatively or postoperatively. Random effects meta-analyses using timing of SRS relative to surgery as covariates were conducted. Meta-regression and Wald-type tests were used to determine the effect of increasing tumor size on the summary estimate, where the null hypothesis was rejected for p &lt; 0.05. RESULTS: Fifteen studies were included (of 314 screened), published between 2012 and 2018 with 854 brain metastases. Preoperative SRS was delivered in 229 lesions. The 1-year LC random effects estimate was 79.1% (95% confidence interval [CI]: 55.9–95.0%; I 2 = 80%) for preoperative SRS and 80.5% (95% CI: 66.3–91.5%; I 2 = 93%) for postoperative SRS (p=0.9). Radionecrosis incidence random effects estimate was 2.1% (95% CI: 0.1–8.6%; I 2 = 36%) for preoperative SRS and 6.3% (95% CI: 1.1–15.4%; I 2 = 90%) for postoperative SRS (p=0.52). CONCLUSIONS: Rates of 1-year LC and RN incidence are similar after preoperative SRS as compared to postoperative SRS for large brain metastases. Results from ongoing prospective clinical trials studying preoperative SRS are important to further investigate these two techniques.
Opioid-Induced Esophageal Dysfunction: Differential Effects of Type and Dose
Snyder, Diana L. , Horsley‐Silva, Jennifer L. , Lacy, Brian E. , Vela, Marcelo F. , Horsley-Silva, Jennifer, Crowell, Michael D. , Ravi, Karthik

Mayo Clinic

American Journal of Gastroenterology | August 9, 2019 | Volume: 114 | Issue: 9 | Pages: 1464-1469

10.14309/ajg.0000000000000369 | PMID 31403963 Get It

OBJECTIVE: Data regarding opioid effects on esophageal function are limited. We previously demonstrated an association between chronic opioid use and esophageal motor dysfunction characterized by esophagogastric junction outflow obstruction, distal esophageal spasm, achalasia type III, and possibly Jackhammer esophagus. Our aim was to characterize the influence of different opioids and doses on esophageal dysfunction. METHODS: Retrospective review of 225 patients prescribed oxycodone, hydrocodone, or tramadol for >3 months, who completed high-resolution manometry from 2012 to 2017. Demographic and manometric data were extracted from a prospectively maintained motility database. Frequency of opioid-induced esophageal dysfunction (OIED, defined as distal esophageal spasm, esophagogastric junction outflow obstruction, achalasia type III, or Jackhammer esophagus on high-resolution manometry, was compared among different opioids. The total 24-hour opioid doses for oxycodone, hydrocodone, and tramadol were converted to a morphine equivalent for dose effect analysis. RESULTS: OIED was present in 24% (55 of 225) of opioid users. OIED was significantly more prevalent with oxycodone or hydrocodone use compared with tramadol (31% vs 28% vs 12%, P = 0.0162), and for oxycodone alone vs oxycodone with acetaminophen (43% vs 21%, P = 0.0482). There was no difference in OIED for patients taking hydrocodone alone vs hydrocodone with acetaminophen. Patients with OIED were taking a higher median 24-hour opioid dose than those without OIED (45 vs 30 mg, P = 0.058). DISCUSSION: OIED is more prevalent in patients taking oxycodone or hydrocodone compared with tramadol. There is greater likelihood of OIED developing with higher doses. Reducing the opioid dose or changing to tramadol may reduce OIED in opioid users.
Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones
Legendre, Christophe, Gooden, Gerald , Huang, Yizhou Peter , Butry, Loren, Johnson, Kyle N., Martinez, Rae Anne , Pierobon, Mariaelena , Petricoin, Emanuel F. , O’Shaughnessy, Joyce , Osborne, C., Tapia, Coya, Buckley, David N. , Glen, Jennifer, Bernstein, Mark, Salhia, Bodour , Schroeder, Mark A. , Tew, Ben Yi , Triche, Timothy J. , Daniel, J. , Sarkaria, Jann N. , Toms, Steven A.

Mayo Clinic

Neuro-Oncology | August 8, 2019 | Volume: 22 | Issue: 1 | Pages: 70-83

10.1093/neuonc/noz137 | PMID 31433055 Get It

Abstract Background The dearth of relevant tumor models reflecting the heterogeneity of human central nervous system metastasis (CM) has hindered development of novel therapies. Methods We established 39 CM patient-derived xenograft (PDX) models representing the histological spectrum, and performed phenotypic and multi-omic characterization of PDXs and their original patient tumors. PDX clonal evolution was also reconstructed using allele-specific copy number and somatic variants. Results PDXs retained their metastatic potential, with flank-implanted PDXs forming spontaneous metastases in multiple organs, including brain, and CM subsequent to intracardiac injection. PDXs also retained the histological and molecular profiles of the original patient tumors, including retention of genomic aberrations and signaling pathways. Novel modes of clonal evolution involving rapid expansion by a minor clone were identified in 2 PDXs, including CM13, which was highly aggressive in vivo forming multiple spontaneous metastases, including to brain. These PDXs had little molecular resemblance to the patient donor tumor, including reversion to a copy number neutral genome, no shared nonsynonymous mutations, and no correlation by gene expression. Conclusions We generated a diverse and novel repertoire of PDXs that provides a new set of tools to enhance our knowledge of CM biology and improve preclinical testing. Furthermore, our study suggests that minor clone succession may confer tumor aggressiveness and potentiate brain metastasis.
Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL
Campbell, Michael J. , Bolen, Jennifer, Vandenberg, Scott , Hoyt, Clifford , Hirst, Gillian L. , Nanda, Rita , Liu, Minetta C. , Asare, Smita , van'tVeer, Laura, DeMichele, Angie, Berry, Don, Esserman, Laura, Investigators, I SPY 2 TRIAL, Hirst, Gillian L , Yau, Christina , Swigart, Lamorna Brown , Yee, Douglas , Berry, Donald A. , Investigators, I SPY 2 TRIAL

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: CT003-CT003

10.1158/1538-7445.am2019-ct003 Get It

Abstract Background: Pembrolizumab (Pembro), an anti-PD-1 immune checkpoint inhibitor, has been approved for the treatment of a variety of cancers. Pembro was recently evaluated in HER2- breast cancer patients in the neoadjuvant I-SPY 2 TRIAL and graduated in the triple negative (TN), HR+HER2-, and HER2- signatures. TN breast cancers tend to have high numbers of immune infiltrates, including T cells and tumor associated macrophages (TAMs). We utilized multiplex multispectral imaging to evaluate the presence and spatial proximity of various immune cell populations as specific predictors of response to Pembro. Methods: Pre-treatment biopsies were available from 54 patients. FFPE sections were immunostained using Opal fluorescence reagent kits on a fully automated Ventana Discovery platform and imaged with a Vectra automated imaging system. Image analyses were performed with a variety of software packages. Immune biomarkers included CD3, CD8, FoxP3, CD68, PD-1, PD-L1, and cytokeratins. Cell densities were determined per area of tissue. Spatial analyses were performed to quantitate proximity of cell types. We used logistic regression with the likelihood ratio test to evaluate associations between pathologic complete response (pCR) with immune cell counts, ratios, and spatial proximity measurements. This analysis was also performed adjusting for HR status, and within receptor subsets, sample size permitting. Our statistics are descriptive rather than inferential and do not adjust for multiple hypothesis testing or multiplicities of other biomarkers outside this study. Results: Densities of CD3+ T cells ranged from 193-5155 cells/mm2, with CD8+ cytotoxic T cells (Tc) ranging from 103 to 3774 cells/mm2 and FoxP3+ Tregs from 0-416 cells/mm2. Densities of PD-1+ T cells and PD-1+ Tc cells ranged from 0-1341 cells/mm2 and 0-698 cells/mm2, respectively. Macrophage cell densities ranged from 84-2644 cells/mm2. PD-L1+ tumor cell densities ranged from 0-2981 cells/mm2. High PD-L1 expression (&gt;=10% of tumor cells positive for PD-L1) was observed in 12% of the cases. Overall T cell density was positively associated with pathological complete response (pCR), as were Treg cell density and PD-1+ T cell density. The ratio of macrophages to Tc cells was negatively associated with response. Finally, the spatial distribution of CD3+ T cells in proximity to cancer cells correlated positively with pCR. Conclusion: Cell density, immune cell ratios and spatial resolution provide insight to response and resistance. We confirmed the observation that T cell density predicts pCR, but more specifically that Treg and PD1+ T cell densities increase the chance of pCR. An increase in macrophages relative to cytotoxic T cells predicts resistance. The closer the T cells are to the tumor, the better the response. These results demonstrate the utility of characterizing the immune microenvironment, in the context of therapy with immuno-oncology agents, not only to predict response, but to gain insight and learn now to potentiate agents and combinations. Citation Format: Michael J. Campbell, Christina Yau, Jennifer Bolen, Scott Vandenberg, Clifford Hoyt, Lamorna Brown-Swigart, Gillian Hirst, Rita Nanda, Minetta Liu, Smita Asare, Laura van'tVeer, Douglas Yee, Angie DeMichele, Don Berry, Laura Esserman, I SPY 2 TRIAL Investigators. Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT003.
Abstract 385: MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma
Wang, Wei‐Lien , Zhang, Xin-Qiao, Song, Jian H. , López, Lidia, Ramachandran, Sumankalai , Hoang, Anh , Garnett, Tyrone, Tu, Shi‐Ming, Gallick, Gary E., Efstathiou, Eleni , Benedict, William F., Chen, Jianfeng , Alhalabi, Omar , Han, Guangchun , Campbell, Matthew T. , Shah, Amishi Yogesh , Wang, Jennifer Rui , Siefker-Radtke, Arlene Odelia , Tu, Shi‐Ming , Titus, Mark Anton , Guo, Charles Chuanhai , Logothetis, Christopher J. , Ho, Thai H. , Wang, Linghua , Gao, Jianjun

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 385-385

10.1158/1538-7445.am2019-385 Get It

Abstract Background: The methylthioadenosine phosphorylase (MTAP) gene encodes an essential enzyme for the salvage pathway of adenosine synthesis and is frequently lost in different types of cancer including urothelial bladder carcinoma. Therefore, MTAP-deficient tumors are theoretically very sensitive to anti-folate agents such as pemetrexed that can effectively block the de novo pathway of adenosine synthesis and as a result, create a state of synthetic lethality. We thus hypothesize that tumor MTAP gene deficiency is associated with response to pemetrexed therapy in bladder cancer. Methods: In this study, we investigated MTAP gene deficiency rates in the TCGA database and confirmed MTAP protein loss by immunohistochemistry using a tumor tissue microarray containing bladder tumor tissues from 151 patients. We then performed in vitro and in vivo studies using MTAP-proficient and MTAP-deficient human bladder cancer cell lines. Functional loss of MTAP was verified with mass spectrometry, which detects its substrate methylthioadenosine (MTA) levels. We also correlated these pre-clinical studies with clinical response data on patients with metastatic bladder cancer treated with pemetrexed. Results: We identified that 27.8% bladder cancer patients have MTAP protein deficiency, which is consistent with exome sequencing data from the TCGA database. In vitro data showed MTAP-deficient human bladder cancer cell lines were significantly more sensitive to pemetrexed, with IC50 at least 40 times lower than MTAP-proficient cell lines. Subsequent knockdown of the MTAP gene in MTAP-proficient cell lines increased sensitivities to pemetrexed treatment. Consistent with the in vitro data, pemetrexed significantly inhibited the growth of MTAP-deficient or knockdown xenograft tumors but not MTAP-proficient tumors. Furthermore, 4 of 4 (100%) patients with MTAP-deficient metastatic bladder cancer responded to pemetrexed treatment, whereas only 1 of 11 (9%) patients with MTAP-proficient metastatic bladder cancer responded to pemetrexed. Conclusion: Our data demonstrate that MTAP gene loss in urothelial bladder cancer leads to a metabolic state of synthetic lethality with pemetrexed therapy. Therefore, bladder tumor MTAP loss should be further investigated as a potential biomarker for selection of patients for anti-folate therapy. Citation Format: Jianfeng Chen, Omar Alhalabi, Guangchun Han, Wei-Lien Wang, Xin-Qiao Zhang, Jian H. Song, Lidia P. Lopez, Sumankalai Ramachandran, Anh G. Hoang, Tyrone Garnett, Matthew Campbell, Amishi Y. Shah, Jennifer Wang, Arlene O. Siefker-Radtke, Shi-Ming Tu, Mark Titus, Charles C. Guo, Gary E. Gallick, Eleni Efstathiou, William F. Benedict, Christopher J. Logothetis, Thai H. Ho, Linghua Wang, Jianjun Gao. MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 385.
Abstract 139: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Zavidij, Oksana, Park, Jihye , Reidy, Mairéad, Ferland, Benjamin, Manier, Salomon , Bustoros, Mark , Huynh, Daisy , Berrios, Brianna, Rahmat, Mahshid , He, Meng Xiao , Maruvka, Yosef E. , Guerriero, Jennifer L. , Goldman, Melissa , Azzi, Jamil, Haradhvala, Nicholas J , Mouhieddine, Tarek H. , Sklavenitis‐Pistofidis, Romanos , Flaifel, Abdallah , Capelletti, Marzia , Liu, Chia‐Jen , Braggio, Esteban , Fonseca, Rafaël , Van Allen, Eliezer M , McCarroll, Steven A. , Getz, Gad , Ghobrial, Irene M.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 139-139

10.1158/1538-7445.am2019-139 Get It

Abstract In multiple myeloma (MM), despite well-characterized precursor states such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), there is a lack of sufficient biomarkers to predict disease progression. Most genomic analyses have studied the malignant plasma cells, however, cancers form a complex ecosystem with the immune and stromal microenvironment. To characterize the cellular composition and transcriptional programs of each component of the tumor and microenvironment at different stages of MM progression, we employed single-cell RNA sequencing on 48K plasma and 40.8K immune microenvironmental cells from a cohort of 22 patients with varying stages of disease progression and 9 healthy donors. Expression profiles of plasma cells revealed clear tumor-specific differences in known oncogenic drivers in MM (MMSET/FGFR3, CCND1 and MAFB) as well as other clonally expressed genes (LAMP5, HIST1H1C, and AREG), distinguishing them from healthy plasma cells. We identified a subset of cycling plasma cells in malignant samples, observing a range of proliferative capacity across disease stages. Furthermore, our approach allowed a unique head-to-head comparison of gene expression changes in normal and malignant plasma cells from the same individual, revealing early alterations in genes related to immune modulation (NKBIA) or controlling transcription and differentiation (EID1). Some alterations were patient-specific, while others, such as MHC I overexpression and CD27 loss, were recurrently observed across subsets of the cohort. Analysis of the BM microenvironment demonstrated significant infiltration of natural killer cells, non-classical monocytes/macrophages, and T cells, even in the earliest stages of the disease. Further investigation revealed upregulation of MHC II expression at the mRNA level in CD14+ monocytes/macrophages and yet, intriguingly, analysis by CyTOF and immunohistochemistry revealed a shift towards intracellular localization of MHC II in these cells. Co-culture with MM cell lines was sufficient to induce the decrease of extracellular MHC II, providing strong evidence for MM-induced compromised antigen presentation by macrophages, and hinting at a mechanism of immune evasion. Together, our results provide a comprehensive view at the complex interplay of the immune and malignant cells in different stages of the disease. We demonstrate the immune response beginning in premalignant conditions to be heterogeneous, including compromised antigen presentation as well as alterations in cellular composition and signaling. Consideration of the type of immunological response may prove valuable in determination of progression risk, as well as open up potential strategies for therapy. Citation Format: Nicholas J. Haradhvala, Oksana Zavidij, Tarek H. Mouhieddine, Romanos Sklavenitis-Pistofidis, Jihye Park, Mairead Reidy, Abdallah Flaifel, Benjamin Ferland, Salomon Manier, Mark Bustoros, Daisy Huynh, Marzia Capelletti, Brianna Berrios, Mahshid Rahmat, Chia-Jen Liu, Meng Xiao He, Esteban Braggio, Rafael Fonseca, Yosef Maruvka, Jennifer Guerriero, Melissa Goldman, Eliezer Van Allen, Steven McCarroll, Jamil Azzi, Gad Getz, Irene M. Ghobrial. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 139.